Title: Clinical trials progression of anti-cancer effects exerted by zoledronic acid
Abstract: Zoledronic acid,the third generation of nitrogen-containing bisphosphonate,is a potent inhibitor of osteoclastic bone resorption by inhibiting osteoclast activity and inducing osteoclast apoptosis and is currently approved for the treatment of tumor-induced hypercalcemia and the reduction and delay of skeletal complications in advanced bone-related malignancies.Data from preclinical studies of zoledronic acid suggest its definite anti-tumor effect.Recently,as several zoledronic acid related clinical trials are carried out,the anti-tumor effect of zoledronic acid attracts people's attention.These clinical trials show that zoledronic acid may improve treatment response of multiple myeloma,breast cancer,prostate cancer and lung cancer including prolonging the disease free survival(DFS) and overall survival(OS).However,some important questions remain,including optimal dosing,initiation and duration of therapy,to be studied in further investigations.Here,we summarized the potential role of zoledronic acid in cancer treatment.
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot